SequelSEC

Enliven Therapeutics, Inc. ELVN

Pharmaceutical Preparations · CIK 0001672619 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$119.66M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Enliven Therapeutics, Inc. (ELVN) reported net income of -$103.69M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Enliven Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Enliven Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$119.66M-$104.55M-$83.53M-$38.79M-$51.44M-$41.70M-$24.12M
Net income-$103.69M-$89.02M-$71.58M-$37.66M-$51.38M-$41.36M-$23.46M
Research & development$85.86M$80.78M$64.57M$31.02M$38.44M$32.15M$19.01M
Weighted-average diluted sharesshares 56.66Mshares 47.07Mshares 35.55Mshares 3.12Mshares 21.66MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailable$1.58M-$51.38MUnavailableUnavailable
Income tax expense$0$232.00K$0$0UnavailableUnavailableUnavailable
Diluted EPS$-1.83$-1.89$-2.01$-12.05$-2.37UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$33.80M$23.78M$18.96M$7.77M$13.00M$9.54M$5.11M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Enliven Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$98.90M$124.12M$100.14M$75.54M$48.31M$47.70M$4.94M
Total assets$476.17M$325.76M$271.87M$83.30M$93.65M$90.84M$33.30M
Current assets$474.88M$318.13M$266.15M$77.75M$92.70M$90.40M$30.62M
Total liabilities$16.57M$15.92M$25.96M$10.37M$7.62M$6.41M$4.38M
Current liabilities$16.57M$15.92M$25.89M$9.72M$7.21M$6.25M$4.20M
Total equity incl. NCI$459.60M$309.84M$245.91M-$76.82M-$42.89M$84.44M-$48.85M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$77.76M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.16M$1.34M$532.00K$3.44M$2.36M$1.97M$1.66M

Cash flow

Enliven Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$70.30M-$73.19M-$61.27M-$32.08M-$46.77M-$37.40M-$21.88M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$173.84M-$36.00M-$148.41M-$612.00K-$1.63M-$16.72M-$24.06M
Financing cash flow$218.87M$133.16M$234.29M-$1.80M$49.10M$96.88M$43.58M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$34.02M$20.17M$12.91M$3.19M$3.84M$2.23M$899.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$300.00K$300.00K$300.00K$200.00KUnavailableUnavailableUnavailable

Derived

Enliven Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio28.66x19.99x10.28x8.00x12.86x14.47x7.29x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELVN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2022-12-31

Difference 149749000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2021-12-31

Difference 128917000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.